Vendor comparison · 2026
PT-141 vendors: 26 compared on COAs and price
OtherAlso known as Bremelanotide, Vyleesi
Evidence tier
Multiple human trials
1 human trial · 3 reviews
- Vendors carrying it
- 26
- 24 with a listed price
- Vendors with checkable COAs
- 8
- 8 publish any certificate
- Lots tested
- 12
- 12 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 23 Sept 2026
- oldest 10 Feb 2026
- Laboratories named
- 5
- most often ILS Laboratories
- Median label gap
- 6.3%
- 42% of lots within 5% of label
- Median purity
- 99.84%
- 12 of 12 lots at 99% or above
- Lowest price per mg
- $2.20
- peer median $4.50
- Publications located
- 121
- researched since 2000
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable PT-141 testing in this index: 4 lots assayed by ILS Laboratories, the newest on 23 Sept 2026. The lowest listed price is $2.20 per mg at Eternal Peptides, against a peer median of $4.50. 26 vendors carrying PT-141 are compared below. 8 publish at least one certificate naming a checkable laboratory, 12 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying PT-141
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 1 / 1 | Freedom Diagnostics Testing | 100.0% | 6.1% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $2.50 (56%) | 4 / 4 | ILS Laboratories | 99.8% | 4.4% | ||
| 3 | Amino ClubISO/IEC 17025Age-gated COAs | 92.298% | $3.00 (67%) | 0 | — | — | — | — | |
| 4 | Ascend ScienceISO/IEC 17025 | 87.794% | $4.20 (93%) | 0 | — | — | — | — | |
| 5 | Modern AminosISO/IEC 17025COAs need an account | 82.797% | $4.10 (91%) | 0 | — | — | — | — | no reportVisit site |
| 6 | CuroISO/IEC 17025 | 81.797% | $5.00 (111%) | 0 | — | — | — | — | no reportVisit site |
| 7 | Bench Grade Peptides | 80.389% | $4.60 (102%) | 2 / 2 | AV Analytics, Freedom Diagnostics Testing | 99.8% | 13.7% | ||
| 8 | Ascension Peptides | 79.689% | $4.90 (109%) | 1 / 1 | MZ Biolabs | 99.5% | 18.5% | ||
| 9 | Simple Peptide | 79.192% | $4.50 (100%) | 1 / 1 | Freedom Diagnostics Testing | 99.7% | 23.0% | ||
| 10 | Koi PeptidesAge-gated COAs | 78.692% | $4.00 (89%) | 0 | — | — | — | — | no reportVisit site |
| 11 | One Aminos | 75.189% | $6.00 (133%) | 1 / 1 | United Laboratories | 99.5% | 6.9% | ||
| 12 | Evo Labs Research | 74.587% | $4.00 (89%) | 0 | — | — | — | — | no reportVisit site |
| 13 | Protide HealthAge-gated COAs | 73.792% | $5.50 (122%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Good Science Bio | 69.771% | $4.00 (89%) | 0 | — | — | — | — | no reportVisit site |
| 15 | Eternal Peptides | 6963% | $2.20 (49%) | 0 | — | — | — | — | no reportVisit site |
| 16 | NeuroLabs Research | 68.891% | $7.19 (160%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Northline LabsISO/IEC 17025 | 68.595% | $9.00 (200%) | 1 / 1 | ILS Laboratories | 99.3% | 2.1% | ||
| 18 | GenX Peptides | 6869% | $4.00 (89%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Evolve Peptides | 65.468% | $4.50 (100%) | 0 | — | — | — | — | no reportVisit site |
| 20 | True Research Labs | 62.268% | $4.90 (109%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Biotech Peptides | 62.160% | $4.50 (100%) | 0 | — | — | — | — | no reportVisit site |
| 22 | Licensed Peptides | 60.687% | $8.80 (196%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Mile High Compounds | 60.591% | $4.50 (100%) | 0 | — | — | — | — | no reportVisit site |
| 24 | Improved Peptides | 58.287% | $6.50 (144%) | 0 | — | — | — | — | no reportVisit site |
| 25 | Vertex Labs | 56.172% | — | 1 / 1 | Freedom Diagnostics Testing | 100.0% | 9.2% | ||
| 26 | BioLongevity Labs | 54.572% | $9.59 (213%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of PT-141 is on file. All 12 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
12 of 12 lots at 99% or above; median 99.84%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 2 |
| ≥99.5% | 10 |
42% of lots within 5% of the labelled mass; median gap 6.3%.
| Range | lots |
|---|---|
| ≤2% | 0 |
| 2–5% | 5 |
| 5–10% | 4 |
| 10–20% | 1 |
| >20% | 2 |
24 vendors, $2.20 to $9.59; median $4.50.
| Range | vendors |
|---|---|
| $2.00–$4.00 | 3 |
| $4.00–$6.00 | 15 |
| $6.00–$8.00 | 3 |
| $8.00–$10.00 | 3 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| ILS LaboratoriesUS | 5 | 2 | 42% | Public lookup |
| Freedom Diagnostics TestingUS | 4 | 4 | 33% | Public lookup |
| AV Analytics | 1 | 1 | 8% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 8% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 8% | Public lookup |
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2000 — 26 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
121 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 12 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.24 pts purity across lots, mean label deviation 9.2%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
26 of 26 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
12 of 12 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is PT-141?
A melanocortin receptor agonist derived from melanotan II, studied for effects on sexual arousal. Its approved form is known as bremelanotide.
Studied in published research for sexual arousal and libido.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
The approved drug bremelanotide (Vyleesi) was studied in human trials for a sexual-desire disorder. PepIndex does not evaluate clinical significance and does not describe administration.
- PT-141 Palatin — Current opinion in investigational drugs (London, England : 2000) (2004)
Peer-reviewed article indexed in PubMed, published in Current opinion in investigational drugs (London, England : 2000) (2004).
- Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment — Journal of midwifery & women's health (2021)
Peer-reviewed article indexed in PubMed, published in Journal of midwifery & women's health (2021).
- Bremelanotide — PubMed (2006)
Peer-reviewed article indexed in PubMed, published in PubMed (2006).
- Bremelanotide — PubMed (2012)
Peer-reviewed article indexed in PubMed, published in PubMed (2012).
- Bremelanotide: First Approval — Drugs (2019)
Peer-reviewed article indexed in PubMed, published in Drugs (2019).
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist — The journal of sexual medicine (2006)
Peer-reviewed article indexed in PubMed, published in The journal of sexual medicine (2006).
- Safety Profile of Bremelanotide Across the Clinical Development Program — Journal of women's health (2002) (2022)
Peer-reviewed article indexed in PubMed, published in Journal of women's health (2002) (2022).
- Targeting the central melanocortin system for the treatment of metabolic disorders — Nature reviews. Endocrinology (2023)
Peer-reviewed article indexed in PubMed, published in Nature reviews. Endocrinology (2023).
Indexed studies4 human-evidence of 4
- Safety Profile of Bremelanotide Across the Clinical Development Program — Human — controlled trial, 2022
Background: Bremelanotide, a melanocortin receptor agonist, is Food and Drug Administration (FDA)-approved for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Methods: Review of bremelanotide's safety profile from the clinical development program (phases 1 through 3). Results: The clinical development program comprised 3500 subjects in 43 completed studies. In the phase 3 studies, subjects took bremelanotide for up to 18 mont…
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder — Systematic review, 2020
Objective: To review data regarding bremelanotide, a recently approved therapy for hypoactive sexual desire disorder (HSDD). Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide, bremelanotide injection, Vyleesi, and melanocortin 4 receptor agonist between January 1, 1996, and December 15, 2019. Reference lists from included articles were also reviewed for pertinent citations. Study Selection/Data Extraction: We inc…
- Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women — Meta-analysis, 2021
Kingsberg et al. described results from two 24-week Phase III trials of bremelanotide for treating hypoactive sexual desire disorder (HSDD) in women. 72.72% of protocol-listed outcomes were not reported by Kingsberg et al., who provided results of 15 secondary measures which were not listed in the study protocols. None of their efficacy outcomes were reported in line with CONSORT data reporting standards and no secondary outcome had a stated rationale or cited evidence of val…
- Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis — Meta-analysis, 2018
To quantify the placebo effect of various pharmacologic modalities including neuromodulators, hormonal agents, and onabotulinum toxin A for female sexual dysfunction. Using Meta-analyses Of Observational Studies in Epidemiology guidelines, we conducted a systematic review of PubMed, EMBASE, ClinicalTrials.gov, and the Cochrane Review databases. Eleven search terms, "female sexual dysfunction" "treatment" in combination with "hypoactive sexual desire," "arousal disorder," "sex…
Evidence digest
What the research on PT-141 actually shows
The indexed literature on PT-141 includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether PT-141 is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.